Chemokines critically orchestrate the tumorigenesis, metastasis, and stemness features of cancer cells that lead to poor outcomes. High plasma levels of transforming growth factor-β1 (TGFβ1) correlate with poor prognostic features in advanced lung cancer patients, thus suggesting the importance of TGFβ1 in the lung tumor microenvironment. However, the role of chemokines in TGFβ1-induced tumor stemness features remains unclear. Here, we clarify the previously undocumented role of CXCL1 in TGFβ1-induced lung cancer stemness features. CXCL1 and its receptor CXCR2 were significantly upregulated in TGFβ1-induced lung cancer stem cells (CSCs). CXCL1 silencing (shCXCL1) suppressed stemness gene expression, tumorsphere formation, colony formation, drug resistance, and in vivo tumorigenicity in TGFβ1-induced lung tumorspheres. Immunohistochemistry staining showed that patients with stage II/III lung cancer had higher expression levels of CXCL1. The levels of CXCL1 were positively associated with lymph node metastasis and correlated with the expression of the CSC transcription factor Oct-4. Furthermore, online database analysis revealed that CXCL1 expression was negatively correlated with lung cancer survival in patients. Patients with high TGFβ1/CXCL1/CD44 co-expression had a worse survival rate. We suggest that CXCL1 serves as a crucial factor in TGFβ1-induced stemness features of lung cancer.
Mollica PoetaVMassaraMCapucettiABonecchiR. Chemokines and chemokine receptors: new targets for cancer immunotherapy.Front Immunol2019;10:379
8.
JungMJRhoJKKimYMJungJEJinYBKoYGLeeJSLeeSJLeeJCParkMJ. Upregulation of CXCR4 is functionally crucial for maintenance of stemness in drug-resistant non-small cell lung cancer cells.Oncogene2013;32:209–21
9.
WaldOShapiraOMIzharU. CXCR4/CXCL12 axis in non small cell lung cancer (NSCLC) pathologic roles and therapeutic potential.Theranostics2013;3:26–33
10.
ScalaS. Molecular pathways: targeting the CXCR4-CXCL12 axis – untapped potential in the tumor microenvironment.Clin Cancer Res2015;21:4278–85
11.
IngangiVMinopoliMRagoneCMottiMLCarrieroMV. Role of microenvironment on the fate of disseminating cancer stem cells.Front Oncol2019;9:82
12.
SyedV. TGF-β signaling in cancer.J Cell Biochem2016;117:1279–87
13.
BellomoCCajaLMoustakasA. Transforming growth factor β as regulator of cancer stemness and metastasis.Br J Cancer2016;115:761–9
14.
LiJShenCWangXLaiYZhouKLiPLiuLCheG. Prognostic value of TGF-β in lung cancer: systematic review and meta-analysis.BMC Cancer2019;19:691
15.
XueVWChungJYCórdobaCAGCheungAHKangWLamEWLeungKTToKFLanHYTangPM. Transforming growth factor-β: a multifunctional regulator of cancer immunity.Cancers2020;12:3099.
16.
ShintaniYFujiwaraAKimuraTKawamuraTFunakiSMinamiMOkumuraM. IL-6 secreted from cancer-associated fibroblasts mediates chemoresistance in NSCLC by increasing epithelial-mesenchymal transition signaling.J Thorac Oncol2016;11:1482–92
17.
HaiderCHnatJWagnerRHuberHTimelthalerGGrubingerMCoulouarnCSchreinerWSchlangenKSieghartWPeck-RadosavljevicMMikulitsW. Transforming growth factor-β and Axl induce CXCL5 and neutrophil recruitment in hepatocellular carcinoma.Hepatology2019;69:222–36
18.
WuYCTangSJSunGHSunKH. CXCR7 mediates TGFβ1-promoted EMT and tumor-initiating features in lung cancer.Oncogene2016;35:2123–32
19.
ShiehJMTsaiYJTsouCJWuWB. CXCL1 regulation in human pulmonary epithelial cells by tumor necrosis factor.Cell Physiol Biochem2014;34:1373–84
20.
NguyenTTKimSJParkJMHahmKBLeeHJ. Repressed TGF-β signaling through CagA-Smad3 interaction as pathogenic mechanisms of Helicobacter pylori-associated gastritis.J Clin Biochem Nutr2015;57:113–20
21.
FangWBMafuvadzeBYaoMZouAPortscheMChengN. TGF-β negatively regulates CXCL1 chemokine expression in mammary fibroblasts through enhancement of Smad2/3 and suppression of HGF/c-Met signaling mechanisms.PLoS ONE2015;10:e0135063
22.
BierieBChungCHParkerJSStoverDGChengNChytilAAakreMShyrYMosesHL. Abrogation of TGF-beta signaling enhances chemokine production and correlates with prognosis in human breast cancer.J Clin Invest2009;119:1571–82
23.
LiXSterlingJAFanKHVessellaRLShyrYHaywardSWMatrisianLMBhowmickNA. Loss of TGF-β responsiveness in prostate stromal cells alters chemokine levels and facilitates the development of mixed osteoblastic/osteolytic bone lesions.Mol Cancer Res2012;10:494–503
24.
ZouALambertDYehHYasukawaKBehbodFFanFChengN. Elevated CXCL1 expression in breast cancer stroma predicts poor prognosis and is inversely associated with expression of TGF-β signaling proteins.BMC Cancer2014;14:781
25.
TangKHMaSLeeTKChanYPKwanPSTongCMNgIOManKToKFLaiPBLoCMGuanXYChanKW. CD133(+) liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling.Hepatology2012;55:807–20
26.
CiummoSLD’AntonioLSorrentinoCFieniCLanutiPStassiGTodaroMDi CarloE. The C-X-C*.Front Cell Dev Biol2021;9:689286
27.
AgarwalPLiHChoiKHuenemanKHeJWelnerRSStarczynowskiDTBhatiaR. TNF-α-induced alterations in stromal progenitors enhance leukemic stem cell growth via CXCR2 signaling.Cell Rep2021;36:109386
28.
GirblTLennTPerezLRolasLBarkawayAThiriotADel FresnoCLynamEHubEThelenMGrahamGAlonRSanchoDvon AndrianUHVoisinMBRotANoursharghS. Distinct compartmentalization of the chemokines CXCL1 and CXCL2 and the atypical receptor ACKR1 determine discrete stages of neutrophil diapedesis.Immunity2018;49:1062–766
29.
SinghSVarneyMSinghRK. Host CXCR2-dependent regulation of melanoma growth, angiogenesis, and experimental lung metastasis.Cancer Res2009;69:411–5
30.
StadtmannAZarbockA. CXCR2: from bench to bedside.Front Immunol2012;3:263
31.
SinclairAParkLShahMDrotarMCalaminusSHopcroftLEKinstrieRGuitartAVDunnKAbrahamSASansomOMichieAMMacheskyLKrancKRGrahamGJPellicanoFHolyoakeTL. CXCR2 and CXCL4 regulate survival and self-renewal of hematopoietic stem/progenitor cells.Blood2016;128:371–83
32.
XuHLinFWangZYangLMengJOuZShaoZDiGYangG. CXCR2 promotes breast cancer metastasis and chemoresistance via suppression of AKT1 and activation of COX2.Cancer Lett2018;412:69–80
33.
CaoZFuBDengBZengYWanXQuL. Overexpression of chemokine (C-X-C) ligand 1 (CXCL1) associated with tumor progression and poor prognosis in hepatocellular carcinoma.Cancer Cell Int2014;14:86
34.
NakashimaMMatsuiYKobayashiTSaitoRHatahiraSKawakamiKNakamuraENishiyamaHOgawaO. Urine CXCL1 as a biomarker for tumor detection and outcome prediction in bladder cancer.Cancer Biomark2015;15:357–64
35.
KasashimaHYashiroMNakamaeHMasudaGKinoshitaHMorisakiTFukuokaTHasegawaTNakaneTHinoMHirakawaKOhiraM. Clinicopathologic significance of the CXCL1-CXCR2 axis in the tumor microenvironment of gastric carcinoma.PLoS ONE2017;12:e0178635
36.
ZhuoCWuXLiJHuDJianJChenCZhengXYangC. Chemokine (C-X-C motif) ligand 1 is associated with tumor progression and poor prognosis in patients with colorectal cancer.Biosci Rep2018;38
37.
ZhangZChenYJiangYLuoYZhangHZhanY. Prognostic and clinicopathological significance of CXCL1 in cancers: a systematic review and meta-analysis.Cancer Biol Ther2019;20:1380–8
38.
DivellaRDanieleASavinoEPalmaFBellizziAGiottaFSimoneGLioceMQuarantaMParadisoAMazzoccaA. Circulating levels of transforming growth factor-beta (TGF-β) and chemokine (C-X-C motif) ligand-1 (CXCL1) as predictors of distant seeding of circulating tumor cells in patients with metastatic breast cancer.Anticancer Res2013;33:1491–7
39.
DhawanPRichmondA. Role of CXCL1 in tumorigenesis of melanoma.J Leukoc Biol2002;72:9–18
40.
KeeleyECMehradBStrieterRM. CXC chemokines in cancer angiogenesis and metastases.Adv Cancer Res2010;106:91–111
41.
AcharyyaSOskarssonTVanharantaSMalladiSKimJMorrisPGManova-TodorovaKLevershaMHoggNSeshanVENortonLBrogiEMassaguéJ. A CXCL1 paracrine network links cancer chemoresistance and metastasis.Cell2012;150:165–78
42.
WeiZWXiaGKWuYChenWXiangZSchwarzREBrekkenRAAwasthiNHeYLZhangCH. CXCL1 promotes tumor growth through VEGF pathway activation and is associated with inferior survival in gastric cancer.Cancer Lett2015;359:335–43
43.
HanDZhangNZhaoSLiuHWangXYangMWangSLiYLiuZTengL. AKIP1 promotes glioblastoma viability, mobility and chemoradiation resistance via regulating CXCL1 and CXCL8 mediated NF-κB and AKT pathways.Am J Cancer Res2021;11:1185–205
44.
SharmaBNawandarDMNannuruKCVarneyMLSinghRK. Targeting CXCR2 enhances chemotherapeutic response, inhibits mammary tumor growth, angiogenesis, and lung metastasis.Mol Cancer Ther2013;12:799–808
45.
ChengYMaXLWeiYQWeiXW. Potential roles and targeted therapy of the CXCLs/CXCR2 axis in cancer and inflammatory diseases.Biochim Biophys Acta Rev Cancer2019;1871:289–312
46.
MiyakeMFuruyaHOnishiSHokutanKAnaiSChanOShiSFujimotoKGoodisonSCaiWRosserCJ. Monoclonal antibody against CXCL1 (HL2401) as a novel agent in suppressing IL6 expression and tumoral growth.Theranostics2019;9:853–67
47.
ChengYMoFLiQHanXShiHChenSWeiYWeiX. Targeting CXCR2 inhibits the progression of lung cancer and promotes therapeutic effect of cisplatin.Mol Cancer2021;20:62
48.
LoHMShiehJMChenCLTsouCJWuWB. Vascular endothelial growth factor induces CXCL1 chemokine release via JNK and PI-3K-dependent pathways in human lung carcinoma epithelial cells.Int J Mol Sci2013;14:10090–106
49.
ShiehJMTsaiYJTsouCJWuWB. CXCL1 regulation in human pulmonary epithelial cells by tumor necrosis factor.Cell Physiol Biochem2014;34:1373–84
50.
YuanMZhuHXuJZhengYCaoXLiuQ. Tumor-derived CXCL1 promotes lung cancer growth via recruitment of tumor-associated neutrophils.J Immunol Res2016;2016:6530410
51.
ChenYSongYDuWGongLChangHZouZ. Tumor-associated macrophages: an accomplice in solid tumor progression.J Biomed Sci2019;26:78
52.
WangNLiuWZhengYWangSYangBLiMSongJZhangFZhangXWangQWangZ. CXCL1 derived from tumor-associated macrophages promotes breast cancer metastasis via activating NF-κB/SOX4 signaling.Cell Death Dis2018;9:880
53.
MiyakeMHoriSMorizawaYTatsumiYNakaiYAnaiSTorimotoKAokiKTanakaNShimadaKKonishiNToritsukaMKishimotoTRosserCJFujimotoK. CXCL1-mediated interaction of cancer cells with tumor-associated macrophages and cancer-associated fibroblasts promotes tumor progression in human bladder cancer.Neoplasia2016;18:636–46
54.
SenGuptaSHeinLEXuYZhangJKonwerskiJRLiYJohnsonCCaiDSmithJLParentCA. Triple-negative breast cancer cells recruit neutrophils by secreting TGF-β and CXCR2 ligands.Front Immunol2021;12:659996
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
